This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa
The drug NOVOMIX-30 contains one active pharmaceutical ingredient (API):
1
Insulin aspart
UNII 978D8U419H - SACCHAROMYCES CEREVISIAE
|
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
A10AD05 | Insulin aspart | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 12238D, 8609D |
Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 526602001159415, 526602002155316 |
Country: CA | Health Products and Food Branch | Identifier(s): 02265435 |
Country: EE | Ravimiamet | Identifier(s): 1084788, 1084823, 1214468, 1214479, 1523786 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 00142009, 00142015, 00142021 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 001490, 006024 |
Country: FR | Base de données publique des médicaments | Identifier(s): 61693569, 64239493, 67832552, 68182431 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 143813, 143865, 201635, 32773, 32781, 376949, 376952, 379926 |
Country: HK | Department of Health Drug Office | Identifier(s): 52604, 61546 |
Country: IE | Health Products Regulatory Authority | Identifier(s): 64275, 68927, 68930, 76140 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 4621 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1004366, 1008620, 1029898, 1029899, 1059246, 1059247, 1059248 |
Country: NL | Z-Index G-Standaard | Identifier(s): 14719509, 14719517 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 121320, 121339, 121347, 65749 |
Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 10731, 9745 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100102170, 100108906 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W08254001, W08254002, W08973001, W08973002 |
Country: SG | Health Sciences Authority | Identifier(s): 12190P, 15480P |
Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 5993082 |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699676950690, 8699676950706 |
Country: ZA | Health Products Regulatory Authority | Identifier(s): 35/21.1/0031 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.